文献速递乳腺癌放疗

即刻乳房重建与乳腺癌放疗后淋巴水肿的关系

Relationship of Immediate Breast Reconstruction and the Development of Lymphedema in Breast Cancer Patients With Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-05-25

该研究回顾性分析2012至2020年440例接受乳房切除加辅助放疗的乳腺癌患者,其中229例接受即刻乳房重建(IR)、211例未重建(NR)。中位随访35个月后26%发生乳腺癌相关淋巴水肿(BCRL),IR组2年累计发生率16.3%低于NR组的28.9%(P = .020)。

要点

  • IR组2年BCRL累计发生率为16.3%,低于NR组的28.9%(P = .020)。
  • 清扫≥15枚腋窝淋巴结(P = .035)与调强放疗(P = .004)与≥2期BCRL发生相关。
  • 初始0或1期BCRL患者中,IR组随访期间进展率33%,低于NR组的60%。

核心结论

  • 乳房切除术后放疗的乳腺癌患者中,清扫≥15枚腋窝淋巴结及调强放疗与淋巴水肿发生显著相关。
  • 即刻乳房重建可能与较低的淋巴水肿发生率相关。

研究设计与样本

  • 回顾性研究,纳入2012至2020年接受乳房切除加辅助放疗的乳腺癌患者440例,IR组229例、NR组211例。
  • 排除放疗前已发生BCRL者30例后,采用倾向性评分匹配,以log-rank分析及多因素Cox回归模型分析相关因素。

主要发现

  • 中位随访35个月,116例(26%)发生BCRL,其中74%为国际淋巴学会2-3期。
  • IR组2年BCRL累计发生率为16.3%,NR组为28.9%(P = .020)。
  • 倾向性评分匹配队列(n = 180)多因素Cox回归显示,清扫≥15枚腋窝淋巴结者更易发生≥2期BCRL(P = .035),接受调强放疗者亦更易发生(P = .004),IR与较低BCRL发生率相关(P = .022)。
  • 初始0或1期BCRL患者中,IR组随访期间进展率为33%,NR组为60%。

关键数值与推荐

  • BCRL事件按国际淋巴学会分期系统定义为0-3级。
  • 2年BCRL累计发生率:IR组16.3%,NR组28.9%(P = .020)。
  • 倾向性评分匹配队列n = 180;清扫≥15枚腋窝淋巴结P = .035,调强放疗P = .004,IR的P = .022。

临床怎么用

  • 对接受乳房切除加辅助放疗的乳腺癌患者,IR可能有助于降低BCRL发生风险。
  • 腋窝淋巴结清扫≥15枚或采用调强放疗的患者应加强淋巴水肿监测与预防。

局限性

  • 为单中心回顾性研究,BCRL事件依赖国际淋巴学会分期定义,可能存在混杂与随访偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Breast cancer-related lymphedema (BCRL) is often challenging to manage, and knowledge of how to prevent it is limited. There are several well-known risk factors, but recent studies have also suggested the potential association of immediate breast reconstruction with lower incidence, albeit with inconclusive results. Thus, we explored the impact of immediate breast reconstruction on lymphedema incidence in patients with breast cancer who underwent a mastectomy and adjuvant radiation therapy (RT). METHODS AND MATERIALS: We retrospectively reviewed 440 patients with breast cancer who underwent a mastectomy with adjuvant RT from 2012 to 2020. Of these, 229 underwent immediate breast reconstruction (IR) group, and 211 underwent no reconstruction (NR) group. BCRL events were defined and graded on a scale of 0-3 following the International Society of Lymphology staging system. After excluding patients who experienced BCRL before RT (n = 30), with propensity score-matching, we used log-rank analysis and multivariate Cox regression models to identify associated factors. Then, the clinical course of BCRL was explored with flow diagrams. RESULTS: After a median follow-up period of 35 months, 116 patients (26%) developed BCRL, with 74% classified as International Society of Lymphology stage 2-3. Two-year actuarial rate of BCRL was 16.3% for the IR group, and 28.9% for the NR group (P = .020). In a multivariate Cox regression of propensity score-matched cohort (n = 180), patients were more likely to develop stage ≥2 BCRL if ≥15 axillary lymph nodes were resected (P = .035), or intensity modulated RT was given (P = .004). However, IR was associated with a lower incidence of BCRL (P = .022). Regarding patients with initial stage 0 or 1 BCRL, the IR group showed a lower rate of progression during follow-up compared with the NR group (33% vs 60%). CONCLUSIONS: In postmastectomy patients with breast cancer, resection of ≥15 axillary lymph nodes, as well as intensity modulated RT, were found to be significantly associated with lymphedema occurrence. Notably, IR may be associated with a lower incidence of lymphedema.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hong SW, Kim EK, Shin HC, et al. Relationship of Immediate Breast Reconstruction and the Development of Lymphedema in Breast Cancer Patients With Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025. PMID: 40425085. doi:10.1016/j.ijrobp.2025.05.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。